News & Updates
Filter by Specialty:
Nutrition literacy not enough to cause basic dietary changes in NAFLD
Patients with nonalcoholic fatty liver disease (NAFLD) continue to follow a poor dietary pattern despite receiving medical recommendations to lose weight and having nutritional literacy and perception that are similar to those without NAFLD, reports a study.
Nutrition literacy not enough to cause basic dietary changes in NAFLD
03 Sep 2023
Do weak opioids increase risk of GI cancers?
Evidence on the association of weak opioids with a higher risk of oesophageal and colorectal cancer is not reliable, but there appears to be a small association with gastric cancer, suggests a study.
Do weak opioids increase risk of GI cancers?
30 Aug 2023
Chemo-induced nausea, vomiting? There’s a dexamethasone-free regimen for that
A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.
Chemo-induced nausea, vomiting? There’s a dexamethasone-free regimen for that
28 Aug 2023
Functional anorectal pain ups incidence of ED, depression, anxiety in men
Men with functional anorectal pain (FARP) are more vulnerable to erectile dysfunction (ED), depression, and anxiety, a study has shown. Moreover, the incidence of these conditions increases with pain severity.
Functional anorectal pain ups incidence of ED, depression, anxiety in men
27 Aug 2023
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.